Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsZing Health Bevacizumab Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentZing HealthPolicy 6927-D

    Medicare Part B Step Therapy Bevacizumab-Oncology Products

    Customize your policy alerts

    Sign up for zing_health Policy 6927-D alerts

    Get alerted when Policy 6927-D changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs Medicare Part B coverage of preferred and non-preferred bevacizumab-oncology products for Zing Health members. Non-preferred products require a clinical exception through prior authorization, subject to step-therapy criteria and applicable Medicare coverage and utilization-management requirements.

    Policy Summary
    PayerZing Health
    PolicyMedicare Part B Step Therapy Bevacizumab-Oncology Products
    Policy CodePolicy 6927-D
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit a prior authorization request for coverage of a non-preferred bevacizumab-oncology product.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2Preferred products
    3Non-preferred products
    365 daysPrior-use lookback
    2Exception pathways

    Non-Preferred Product Coverage Exceptions

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Non-preferred product coverage exception

    Coverage for a non-preferred product is provided when either of the following criteria is met:

    Non-preferred product exception

    • Prior treatment: Member has received treatment with the requested non-preferred product in the past 365 days.within the past 365 days
    • Intolerable adverse events: Member has had a documented intolerable adverse event to both preferred products, and the adverse event was not an expected adverse event attributed to the active ingredient as described in the prescribing information.both preferred products

      This includes a known adverse reaction to both the reference product and biosimilar products.

    An adverse event that is an expected adverse event attributable to the active ingredient, as described in the prescribing information, does not satisfy the intolerance exception. This includes a known adverse reaction to both the reference product and biosimilar products.

    Prior Authorization and Documentation Requirements

    Prior Authorization

    Prior Authorization and Product Selection

    Prior authorization is required to request a non-preferred bevacizumab-oncology product. Coverage may be approved through a clinical exception when circumstances exclude use of a preferred product; preferred products may still require a separate clinical prior authorization review. This step therapy applies to all members requesting a non-preferred product, in addition to applicable NCD, LCD, and Medicare Part B utilization-management requirements.

    • Preferred: Mvasi (bevacizumab-awwb) and Zirabev (bevacizumab-bvzr).
    • Non-preferred: Alymsys (bevacizumab-maly), Avastin (bevacizumab), and Vegzelma (bevacizumab-adcd).
    • Submit clinical documentation supporting the exception request and the requested product selection.
    Step Therapy

    Non-Preferred Product Exception Criteria

    Coverage for a non-preferred product is provided when either of the following exception pathways is met: documented treatment with the requested product within the lookback period, or a documented intolerable adverse event to both preferred products that is not an expected active-ingredient-related adverse event.

    • The request must satisfy at least one qualifying pathway.
    • The exception process applies to all members requesting treatment with a non-preferred product.

    Unsupported block type: documentationเcallout

    Unsupported block type: documentation

    Denial Risk

    Exception Criteria Not Met

    A non-preferred product may be denied when neither qualifying exception pathway is met. Approval is not supported if there is no documented use of the requested product within the past 365 days and no documented intolerable adverse event to both preferred products meeting the policy requirements.

    • Do not rely on intolerance to only one preferred product.
    • Expected adverse events attributed to the active ingredient do not satisfy the intolerance exception.
    • Submit additional documentation when the exception criteria are not established.

    Policy Background

    This policy establishes preferred and non-preferred bevacizumab-oncology products for Medicare Part B treatment. It follows a Medicare Part B Advanced Biosimilars First strategy, requiring selection of designated preferred products before coverage of specified non-preferred products, subject to clinical exceptions and applicable Medicare coverage and utilization-management requirements.

    Non-preferred products may be covered when a clinical exception is approved through prior authorization. The exception pathways are documented prior use of the requested non-preferred product within the past 365 days or a documented intolerable adverse event to both preferred products that is not an expected adverse event attributable to the active ingredient.

    Program and Product Definitions

    Preferred products
    DefinitionBevacizumab-oncology products designated by the plan for first-line product selection.
    Preferred productsMvasi (bevacizumab-awwb) and Zirabev (bevacizumab-bvzr).
    Authorization notePreferred products may still require a clinical prior authorization review.
    Non-preferred products
    DefinitionBevacizumab-oncology products that require an approved clinical exception through prior authorization.
    Non-preferred productsAlymsys (bevacizumab-maly), Avastin (bevacizumab), and Vegzelma (bevacizumab-adcd).
    Coverage pathwayNon-preferred products are subject to an exception process through prior authorization.
    Medicare Part B Advanced Biosimilars First
    ProgramMedicare Part B Advanced Biosimilars First.
    Product requirementUse designated preferred advanced biosimilars before coverage of specified non-preferred products.
    Exception pathwayCoverage of non-preferred products is available through clinical exceptions handled by prior authorization.

    Initial Non-Preferred Product Exception

    Initial non-preferred product exception

    Coverage for a non-preferred product is provided when either of the following criteria is met:

    Non-preferred product exception

    • Prior treatment: Member has received treatment with the requested non-preferred product in the past 365 days.within the past 365 days
    • Intolerable adverse events: Member has had a documented intolerable adverse event to both preferred products, and the adverse event was not an expected adverse event attributed to the active ingredient as described in the prescribing information.both preferred products

      This includes a known adverse reaction to both the reference product and biosimilar products.

    Preferred Product Sequence

    StepPreferred-product requirementExceptions
    1Use a preferred bevacizumab-oncology product.A non-preferred product may be covered if the member received the requested product within the past 365 days, or had a documented intolerable adverse event to both preferred products. The adverse event must not be an expected adverse event attributable to the active ingredient as described in the prescribing information.

    Preferred Bevacizumab-Oncology Products

    Billing Rule

    Mvasi is preferred over Avastin

    Mvasi (bevacizumab-awwb) is preferred under the Medicare Part B Advanced Biosimilars First program for Avastin (bevacizumab) product selection.

    Billing Rule

    Zirabev is preferred over Avastin

    Zirabev (bevacizumab-bvzr) is preferred under the Medicare Part B Advanced Biosimilars First program for Avastin (bevacizumab) product selection.

    Policy Summary
    PayerZing Health
    PolicyMedicare Part B Step Therapy Bevacizumab-Oncology Products
    Policy CodePolicy 6927-D
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit a prior authorization request for coverage of a non-preferred bevacizumab-oncology product.
    SourceLink
    On This Page
    Non-Preferred Product Coverage ExceptionsPrior Authorization and Documentation RequirementsPolicy BackgroundProgram and Product DefinitionsInitial Non-Preferred Product ExceptionPreferred Product SequencePreferred Bevacizumab-Oncology Products